New to Meducation?
Sign up
Already signed up? Log In
view moderators

MacularDegeneration

Category

Preview
0
10

Two Expensive Diabetic Macular Edema Drugs Not Cost-effective

Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found.  
medscape.com
over 3 years ago
Preview
0
8

Higher priced drugs are not cost effective for diabetic macular edema, US study finds

In comparsion with treatment with the low cost antivascular endothelial growth factor (VEGF) drug bevacizumab (Avastin), the more expensive alternatives aflibercept (Eylea) and ranibizumab (Lucentis) are not cost effective for diabetic macular edema, a new study has found.1  
feeds.bmj.com
over 3 years ago
Preview
0
0

Persistent Diabetic Macular Edema: Converting Eyes to Aflibercept

In patients with persistent diabetic macular edema, switching from an older VEGF inhibitor to a newer one may improve outcomes. Conversion to aflibercept may now be another option.  
medscape.com
over 3 years ago
Preview
0
0

Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause

Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows.  
medscape.com
over 3 years ago
Preview
0
0

AMD: Untreated Sleep Apnea May Reduce Response to Bevacizumab

A small, single-center study has suggested untreated sleep apnea reduces treatment response to bevacizumab in patients with exudative age-related macular degeneration.  
medscape.com
over 3 years ago
Preview
0
0

Low Vitamin D Levels Linked to Macular Degeneration Risk

Adults with the lowest levels of circulating vitamin D levels had the highest risk for age-related macular degeneration, particularly late-stage, compared with those with the highest levels.  
medscape.com
over 3 years ago
Preview
0
0

Modifiable Risk Factors for AMD: The Role of Statins

If cardiovascular disease and age-related macular degeneration (AMD) share some pathophysiologic mechanisms, would interventions that reduce cardiovascular disease help reduce the progression of AMD?  
medscape.com
over 3 years ago
Preview
0
0

Dexamethasone Implant Helps Some With Diabetic Macular Edema

An intravitreal dexamethasone implant (Ozurdex, Allergan) can prompt improvement in patients with diabetic macular edema refractory to multiple anti-vascular endothelial growth factor (anti-VEGF) injections, according to Korean researchers.  
medscape.com
over 3 years ago
Preview
0
0

Delayed Visual Improvements in AMD Continue With Ranibizumab Treatment

Visual improvements in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab continue after macular edema resolves, researchers report.  
medscape.com
over 3 years ago
Preview
0
0

Aflibercept for Macular Edema Secondary to Central RVO

Aflibercept may be an effective therapeutic option for macular edema due to central retinal vein occlusion that did not respond to treatment with bevacizumab or ranibizumab.  
medscape.com
over 3 years ago
Preview
0
6

Glaucoma Drops May Help in Refractory AMD

When age-related macular degeneration (AMD) is refractory to intravitreous anti-vascular endothelial growth factor (anti-VEGF), adding dorzolamide-timolol eye drops may be helpful, according to a small pilot study.  
medscape.com
over 3 years ago
Preview
0
1

Aflibercept is better drug for diabetic macular oedema, study finds

Three drugs to treat diabetic macular oedema—aflibercept, bevacizumab, and ranibizumab—are equally effective for patients with mild vision loss, a two year trial funded by the US National Institutes of Health shows. However, for patients with moderate or worse vision loss aflibercept produced the greatest gains, the study published in Ophthalmology showed.1  
feeds.bmj.com
over 3 years ago
Preview
0
0

Aflibercept is better drug for diabetic macular oedema, study finds

Three drugs to treat diabetic macular oedema—aflibercept, bevacizumab, and ranibizumab—are equally effective for patients with mild vision loss, a two year trial funded by the US National Institutes of Health shows. However, for patients with moderate or worse vision loss aflibercept produced the greatest gains, the study published in Ophthalmology showed.1  
feeds.bmj.com
over 3 years ago
Preview
0
5

Atorvastatin: A Drusen Disintegrator?

Can treatment with a high-dose statin for age-related macular degeneration resolve drusen and improve visual acuity?  
medscape.com
over 3 years ago
Preview
0
5

Sleep Patterns Linked to Macular Disease

Adults who get more than 8 hours of sleep per night are at increased risk for advanced dry age-related macular degeneration.  
medscape.com
over 3 years ago
Preview
0
6

Antiplatelet Drugs May Increase Retinal Bleeding in Wet AMD

A new study has shown a significant association between retinal hemorrhage and anticoagulant or antiplatelet use in patients who have neovascular age-related macular degeneration and hypertension.  
medscape.com
over 3 years ago
Preview
0
0

Survey Shows US AMD Incidence Far Lower Among Blacks

Black people have one tenth the incidence of late age-related macular degeneration compared with white people in the United States, a new survey has shown.  
medscape.com
over 3 years ago
Preview
0
0

Anti-VEGF Therapy for Persistent Diabetic Macular Edema

In patients with persistent diabetic macular edema (DME), there may be long-term benefits to be gained from continuing with anti-vascular endothelial growth factor (anti-VEGF) therapy, according to a post hoc analysis of a Diabetic Retinopathy Clinical Research (DRCR) Network trial.  
medscape.com
almost 4 years ago
Preview
0
0

Is Cataract Surgery Safe for Patients With Wet AMD?

Does cataract surgery contribute to the progression of wet age-related macular degeneration?  
medscape.com
almost 4 years ago
Preview
0
0

AMD-Associated Genetic Variants Identified

A large study has identified genetic variants behind the difficult-to-treat 'wet' age-related macular degeneration.  
medscape.com
almost 4 years ago